All Site

Does quantative fFN have more utility than qualitative fFN?

freetrial3Early detection of high risk pregnancies is an important priority to ensure timely introduction of close monitoring and preventative treatment. Women presenting with signs and symptoms of preterm labour continue to represent a clinical challenge. High numbers of patients are unnecessarily admitted, treated or transferred. Of the patients admitted to the hospital for threatened preterm labour (PTL) 85% do not deliver within the next 7 days.1

Currently many Australian maternity units rely on the Quantitative Fetal Fibronectin (QfFN) test to assess the risk of preterm labour. However studies have shown that the quantification of fetal fibronectin has shown little improvement in the Positive Predictive Value (PPV).2

prediction spontaneous preterm birth

While a Negative Predictive Value (NPV) will give you an indication of how likely it is that a woman won’t go into labour, given the risks associated with preterm birth, the instance of admission and the possibility of intervention is still high.

An accurately high Positive Predictive Value is also required, giving clinicians the opportunity to intervene where necessary and allow administration of therapeutics to prepare mother and baby for birth.


Despite the introduction of new diagnostic technologies, currently available tests have extremely poor predictive values for imminent delivery.3

A European multicenter cohort study conducted in 10 centers in 5 countries with 502 patients that were between 24-34w GA with intact membranes and underwent fFN testing & CL measurement, concluded that ‘QfFN adds no further benefit in the prediction of delivery <7 days compared to a model with qualitative fFN and cervical length'.4

A superior test for assessing the risk of preterm birth

“PartoSure has consistently demonstrated a high NPV and a statistically superior PPV (p<0.05) for the prediction of spontaneous preterm delivery within 7 days in patients with threatened preterm labour.”7

The PartoSure Test is a rapid, non-invasive strip test for the detection of placental alpha microglobulin-1 (PAMG-1) in patients between 20 to 36+6 weeks gestation presenting with signs and symptoms suggestive of preterm labour.

PartoSure’s unique features include:

  • High Positive (PPV) and Negative Predictive Value (NPV)
  • Applicable shortly after vaginal exam
  • Speculum examination optional
  • Results in 5 minutes or less
  • No special equipment or training needed
  • Wide gestational age range between 20 and 37 weeks.



In conclusion, PartoSure is the only Time to Delivery test with both high PPV and NPV results that provides consistent performance across studies and geographies to assess the risk of preterm birth. It is a rapid bedside test that can be performed by doctors, nurses and midwives, with or without speculum examination, giving accurate results in minutes.


1. Lotfi et al. World Congress of Perinatal Medicine (WCPM). 2015 (submitted abstract). 2. Abbott DS, Radford SK, Seed PT, Tribe RM, Shennan AH.CAm J Obstet Gynecol. 2013 Feb;208(2):122. 3. Berghella et al. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database of Systemic Reviews 2008, Issue 4.Art. No.:CD006843. (Systemic review). 4. Bruijn et al. G. Supplement to JANUARY 2015 American Journal of Obstetrics & Gynecology. S191-S192. 5. Nikolova et al. J Perinat Med. 2014 Jul;42(4):473-7. 6. Nikolova et al. J Perinat Med. 2015 Jan 6. 7. Heverhagen et al. Swiss Society of Obstetrics and Gynecology Annual Congress. 2015 (abstract). 8. Bolotskikh et al. Scientific and Practical Journal of Obs and Gyn Russian Fed. 2015; 2:94-98. 9. Van Holsbeke et al. World Congress of Perinatal Medicine (WCPM). 2015 (submitted abstract).

partosure logoIVT.jpg